Interventions Pharmacologic

Friday, May 15, 2015: 11:30 AM-1:30 PM
Imperial Ballroom (Grand America Hotel)
11:30 AM
126 A Randomized, Placebo Controlled Trial of Omega-3 Fatty Acids in the Treatment of Young Children with Autism
D. Mankad A. Dupuis S. Smile W. Roberts J. A. Brian T. B. Lui L. Genore D. Zaghloul A. Iaboni M. Marcon E. Anagnostou
11:30 AM
127 Atomoxetine Tolerability and Adverse Events in Autism Spectrum Disorders in the Multisite Charts Study
J. A. Hellings S. L. Hyman B. L. Handen T. Smith P. Corbett-Dick R. Tumuluru L. E. Arnold M. G. Aman
11:30 AM
128 Atomoxetine, Placebo, and Parent Training in Autism
T. Smith B. L. Handen M. G. Aman L. E. Arnold S. L. Hyman X. Pan K. A. Buchan-Page
11:30 AM
Citalopram Treatment of Young Children with Autism Spectrum Disorder (ASD): Correlation with Maternal History of Depression (Withdrawn)
A. W. Zimmerman K. Singh S. L. Connors
11:30 AM
Developing and Testing an Intervention to Reduce Challenging Behaviors within Community and School-Based Mental Health Services (Withdrawn)
L. I. Brookman-Frazee W. Ganger M. Dyson C. Chlebowski M. Baker-Ericzen N. Stadnick
11:30 AM
131 Effect of Treatment with OMEGA-3 Polyunsaturated Fatty Acids on Behavioural Measures in Children and Adolescents with Autism Spectrum Disorders
C. Moreno R. Calvo Escalona S. Gutierrez M. Graell J. Romo M. L. Dorado M. Giraldez C. Llorente C. Arango M. Parellada
11:30 AM
134 From Experimental to Investigational: The Potential for Eye Tracking As a Biomarker for Outcome in Clinical Trials
F. Shic M. del Valle Rubido E. Hollander S. S. Jeste J. T. McCracken L. Scahill O. Khwaja L. Squassante S. Sadikhov J. Dukart E. S. Kim M. Perlmutter E. Sharer R. Paul R. J. Jou M. C. Lyons T. Apelian G. Berlin C. J. Ferretti A. Gavaletz R. L. Loomis J. N. Cowen T. Shimizu B. P. Taylor C. A. Wall R. Noone L. N. Antar L. Boak P. Fontoura D. Umbricht
11:30 AM
136 Irritability, Agitation and Agression in Persons with ASD: The ATN Pathway for Evaluation and Individualized Treatment Planning
A. Whitaker K. Morton R. A. Vasa A. Y. Hardan L. K. Fung A. A. Nozzolillo R. Mahajan P. Bernal J. Veenstra-Vander Weele D. L. Coury A. Silberman A. Wolfe
11:30 AM
138 Meta-Analysis of Pharmacotherapies for Treating Irritability, Agitation and Aggression in ASD
L. K. Fung R. Mahajan A. A. Nozzolillo P. Bernal A. Krasner B. Jo D. L. Coury A. Whitaker J. Veenstra-Vander Weele A. Y. Hardan
11:30 AM
140 Pharmacological Modulation of Excitatory/Inhibitory Balance in Autism Spectrum Disorder
L. A. Ajram J. Horder M. A. Mendez A. Galanopoulos L. Brennan R. Wichers D. J. Lythgoe S. C. Williams D. G. Murphy G. M. McAlonan
11:30 AM
142 Preliminary Characterization of Medication Use in a Multicenter Sample of Pediatric Inpatients with Autism Spectrum Disorder
E. V. Pedapati L. K. Wink C. Erickson R. Gabriels C. A. Beresford D. Kaplan E. M. Morrow M. Siegel
11:30 AM
144 Results from a Phase I Proof-of-Mechanism Study with a Vasopressin 1a Receptor Antagonist in ASD
D. Umbricht M. del Valle Rubido F. Shic J. T. McCracken L. Scahill O. Khwaja L. Squassante L. Boak F. Bolognani P. Fontoura C. A. Wall R. J. Jou R. L. Loomis M. C. Lyons A. Gavaletz J. N. Cowen T. Apelian S. S. Jeste C. J. Ferretti B. P. Taylor G. Berlin R. Noone L. N. Antar E. Hollander
11:30 AM
11:30 AM
148 Trichuris Suis Ova (TSO) As an Immune-Inflammatory Treatment for Repetitive Behaviors in ASD
E. Hollander C. J. Ferretti B. P. Taylor R. Noone E. Racine E. Doernberg
11:30 AM
149 Uptake 2 Transporter Blockade Can Ameliorate Sociability Deficits
G. G. Gould C. M. Smolik W. Koek M. A. Javors L. C. Daws